Advances in ovarian cancer treatment using a combination of statins with other drugs

Area of Science:

• Oncology
• Pharmacology

Background:

• Targeted anti-cancer drugs show limited efficacy in ovarian cancer.
• Conventional drug repositioning, like using statins, is a cost-effective alternative.
• Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), a target implicated in TP53-mutant ovarian tumors.

Purpose of the Study:

• To explore the potential of statins in ovarian cancer treatment.
• To investigate the synergistic role of statins in combination therapies for ovarian cancer.

Main Methods:

• Review of epidemiological studies and in vitro experiments on statins' anti-cancer effects.
• Analysis of HMGCR expression in TP53-mutant ovarian tumors.
• Evaluation of clinical trial outcomes for statins in ovarian cancer.

Main Results:

• Statins demonstrate anti-ovarian cancer effects, particularly in tumors with high TP53 mutation rates and HMGCR expression.
• Prospective clinical trials of statins as a sole agent yielded suboptimal results.
• Statins appear to function more effectively in a synergistic capacity rather than as a standalone treatment.

Conclusions:

• Statins hold promise as a synergistic agent in ovarian cancer therapy, not as a primary treatment.
• Understanding statins' mechanisms in ovarian cancer is crucial for developing precise combination therapies.
• Targeting HMGCR in TP53-mutant ovarian cancers with statins warrants further investigation for combination strategies.